This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wirden, M.
Right arrow Articles by Marcelin, A.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wirden, M.
Right arrow Articles by Marcelin, A.-G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2006, p. 2553-2556, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00092-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients

Marc Wirden,1,4* Bénédicte Roquebert,4 Anne Derache,4 Anne Simon,2 Claudine Duvivier,3 Jade Ghosn,3 Stephanie Dominguez,3 Véronique Boutonnet,1 Zaina Ait-Arkoub,1 Christine Katlama,3 Vincent Calvez,1,4 and Anne-Genevieve Marcelin1,4

Departments of Virology,1 Internal Medicine,2 Infectious Diseases, Pitié-Salpêtrière Hospital, Paris, France,3 Université Pierre et Marie Curie-Paris 6, EA 2387, Paris, F-75013 France4

Received 23 January 2006/ Returned for modification 24 March 2006/ Accepted 25 April 2006

We analyzed 3,475 human immunodeficiency virus sequences and 241 therapeutic histories. The L74I mutation was carried by 7% of viruses. L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz.

* Corresponding author. Mailing address: Pitié-Salpêtrière Hospital, Department of Virology, CERVI, 83, blvd de l'hôpital, 75013 Paris, France. Phone: 33142177401. Fax: 33142177411. E-mail: marc.wirden{at}psl.aphp.fr.

Antimicrobial Agents and Chemotherapy, July 2006, p. 2553-2556, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00092-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»